BioCentury | Apr 20, 2018
Clinical News

Prescient reports 50% ORR in Phase Ib of PTX-200 for breast cancer

...10 evaluable patients with HER2-negative breast cancer in a U.S. Phase Ib trial showing that PTX-200...
...Phase II dose is 35 mg/m 2 PTX-200. Prescient Therapeutics Ltd. (ASX:PTX), Melbourne, Australia Product: PTX-200...
...Treat HER2-negative breast cancer Endpoint: Pathologic complete response rate Status: Phase Ib data Milestone: NA PTX-200...
BioCentury | Aug 8, 2016
Emerging Company Profile

Interrogating immunity

OncoResponse Inc. is repurposing Theraclone Sciences Inc .'s I-STAR discovery platform to identify antibodies produced by exceptional responders to cancer immunotherapy. By tapping patients' natural immune responses, OncoResponse hopes to find novel immune targets and...
BioCentury | Nov 3, 2014
Company News

AKTivate Therapeutics, Virax deal

...100 million additional shares valued at A$1 million ($879,400) tied to clinical milestones. Virax gains TCN-P...
...of TCN-P for leukemia in early 2015. Virax said clinical milestone payments are based upon TCN-P...
BioCentury | Dec 9, 2013
Company News

PharmAthene, Theraclone deal

Biodefense company PharmAthene terminated a July agreement with antibody company Theraclone to merge in a stock deal. PharmAthene will pay Theraclone a $1 million termination fee. PharmAthene would have been the surviving entity, of which...
BioCentury | Sep 16, 2013
Clinical News

Human anti-M2e antibody: Phase IIa data

Data from 48 evaluable healthy volunteers with laboratory-confirmed influenza A infection in a double-blind, U.K. Phase IIa influenza A viral challenge trial showed that a single dose of 40 mg/kg IV TCN-032 given 24 hours...
BioCentury | Sep 16, 2013
Clinical News

TCN-202: Phase IIa started

Theraclone began a Phase IIa trial in up to 20 renal transplant recipients to evaluate TCN-202 for 10 weeks following transplantation. TCN-202 has Orphan Drug designation to treat congenital CMV infection. PharmAthene Inc. (NYSE-M:PIP, Annapolis,...
BioCentury | Sep 10, 2013
Clinical News

Theraclone reports Phase IIa data for anti-flu mAb

Theraclone Sciences Inc. (Seattle, Wash.) said a single dose of TCN-032 given 24 hours after viral inoculation missed the primary endpoint of reducing the proportion of subjects with grade two or higher influenza symptoms or...
BioCentury | Sep 9, 2013
Product Development

Viral persistence

Theraclone Sciences Inc. was to present data Sept. 8 showing TCN-032 missed the primary endpoint in a Phase IIa influenza viral challenge study. However, the company says the endpoint, rather than the mAb, was the...
BioCentury | Aug 5, 2013
Company News

PharmAthene, Theraclone deal

Biodefense company PharmAthene and antibody company Theraclone will merge in a stock deal, which is expected to close next quarter. PharmAthene will be the surviving entity. Theraclone will own 50% of the surviving entity. Theraclone's...
BioCentury | Apr 8, 2013
Clinical News

TCN-202: Phase I data

Top-line data from a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 40 healthy volunteers showed that IV TCN-202 was well tolerated with no dose-limiting toxicities (DLTs) or serious adverse events reported. No antibodies against...
Items per page:
1 - 10 of 28